

## Hydroxychloroquine

S

### Retinal detachment while off label use: case report

A 49-year-old man developed retinal detachment while receiving off label hydroxychloroquine for COVID-19.

The man was admitted with a 7-day history of weakness, cough and expectoration. He had been receiving antiretroviral therapy with tenofovir/emtricitabine and dolutegravir for HIV infection since 2008. On admission, he was diagnosed with COVID-19. He started receiving off label oral hydroxychloroquine 400mg twice a day as loading dose followed by 200mg two times daily as maintenance dose for 5 days, oral oseltamivir 75mg twice daily for 5 days and IV moxifloxacin 400mg once daily for 7 days. Additionally, he received cotrimoxazole [trimethoprim-sulfamethoxazole] for PCP prophylaxis. He also received unspecified low molecular weight heparins. On hospital day 5, a follow-up SARS CoV-2 PCR turned negative. Subsequently, he was discharged on hospital day 15. One month following discharge, he developed retinal detachment [*outcome not stated*].

Turken M, et al. The course of covid-19 in four patients with hiv during the pandemic. Current HIV Research 19: 286-291, No. 3, 2021. Available from: URL: <http://doi.org/10.2174/1570162X18666201201093540>

803579249